Trials / Completed
CompletedNCT03432702
Horizontal Ridge Augmentation With or Without Autogenous Block Grafts
Horizontal Ridge Augmentation With Guided Bone Regeneration Using Particulate Xenogenic Bone Substitutes With or Without Autogenous Block Grafts: A Randomized Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Universidad Científica del Sur · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
To evaluate dimensional bone alterations following horizontal ridge augmentation using guided bone regeneration (GBR) with or without autogenous block graft (ABG) for the rehabilitation of atrophic jaws with dental implants.
Detailed description
Forty-two patients with 42 severe horizontal bone atrophy sites in the maxilla or mandible will be randomly assigned to two groups: ABG or GBR. In the ABG group, a combination of ABG with particulate xenograft, covered with collagen membrane, will be used, while only a combination of particulate xenograft and collagen membrane alone will be in the GBR group. After 6-9 months of healing, implants were inserted. All implants will be definitively restored 6 months after implant placement. Radiographic examination (cone beam computed tomograms, CBCT) will be performed to evaluate the amount of horizontal bone width (HBW) gain immediately after bone grafting procedure (T0), at 6 months (T6), and at 18 months (T18). Patient demographic information, amount of width augmentation, implant survival, complications, and contributing factors will be gathered and analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Horizontal ridge augmentation | Surgical procedures performed to provide the alveolar ridge with enough width and height to allow for the prosthetically driven implant placement. |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2015-09-01
- Completion
- 2017-06-01
- First posted
- 2018-02-14
- Last updated
- 2018-02-14
Locations
1 site across 1 country: Peru
Source: ClinicalTrials.gov record NCT03432702. Inclusion in this directory is not an endorsement.